[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2780029A4 - Formulations orales de leptine et leurs utilisations - Google Patents

Formulations orales de leptine et leurs utilisations

Info

Publication number
EP2780029A4
EP2780029A4 EP11875859.8A EP11875859A EP2780029A4 EP 2780029 A4 EP2780029 A4 EP 2780029A4 EP 11875859 A EP11875859 A EP 11875859A EP 2780029 A4 EP2780029 A4 EP 2780029A4
Authority
EP
European Patent Office
Prior art keywords
oral
leptin formulations
leptin
formulations
oral leptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11875859.8A
Other languages
German (de)
English (en)
Other versions
EP2780029A1 (fr
Inventor
Moise Bendayan
Phillippe Cammisotto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Publication of EP2780029A1 publication Critical patent/EP2780029A1/fr
Publication of EP2780029A4 publication Critical patent/EP2780029A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2207Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2235Secretins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP11875859.8A 2011-11-18 2011-11-18 Formulations orales de leptine et leurs utilisations Withdrawn EP2780029A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2011/050720 WO2013071396A1 (fr) 2011-11-18 2011-11-18 Formulations orales de leptine et leurs utilisations

Publications (2)

Publication Number Publication Date
EP2780029A1 EP2780029A1 (fr) 2014-09-24
EP2780029A4 true EP2780029A4 (fr) 2015-06-24

Family

ID=48428867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11875859.8A Withdrawn EP2780029A4 (fr) 2011-11-18 2011-11-18 Formulations orales de leptine et leurs utilisations

Country Status (3)

Country Link
EP (1) EP2780029A4 (fr)
CA (1) CA2855545A1 (fr)
WO (1) WO2013071396A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532292A (ja) * 2014-08-11 2017-11-02 オルバニー メディカル カレッジ ミリストイル化レプチン関連ペプチド及びその使用
AU2022244505A1 (en) * 2021-03-23 2023-02-09 Kashiv Biosciences, Llc An extraction process of pancrelipase and evaluation threof
CN115463094B (zh) * 2021-06-10 2023-07-04 北京微著新材科技有限公司 一种口服放疗防护剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045869A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006133333A2 (fr) * 2005-06-07 2006-12-14 The Rockefeller University Stimulation de proliferation de lymphocytes pancreatiques b
WO2007109354A2 (fr) * 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
EP2470197A4 (fr) * 2009-08-24 2013-03-13 Aegis Therapeutics Llc Composition pour l absorption et l action prolongée de peptides liés à la leptine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045869A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006133333A2 (fr) * 2005-06-07 2006-12-14 The Rockefeller University Stimulation de proliferation de lymphocytes pancreatiques b
WO2007109354A2 (fr) * 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013071396A1 *

Also Published As

Publication number Publication date
EP2780029A1 (fr) 2014-09-24
WO2013071396A1 (fr) 2013-05-23
CA2855545A1 (fr) 2013-05-23

Similar Documents

Publication Publication Date Title
TWI559936B (en) Oral care compositions
HK1183802A1 (en) Therapeutic oral composition
ZA201206666B (en) Oral care composition
HUE033071T2 (hu) Vakcinakészítmények
SG11201401056SA (en) Oral care compositions
AU2012398397A8 (en) Oral care composition
ZA201206301B (en) Oral care composition
ZA201205804B (en) Oral care compositions
PT2605757E (pt) Formulações à base de nalbufina e suas utilizações
HK1203432A1 (en) Oral care compositions
ZA201206068B (en) Oral care compositions
HK1203402A1 (en) Oral care compositions
PL2555829T3 (pl) Kompozycje do pielęgnacji jamy ustnej
HK1183228A1 (zh) 口服藥物治療方法和組合物
ZA201404443B (en) Oral care compositions
HK1200705A1 (en) Oral care compositions
ZA201305285B (en) Oral care compositions
HK1203385A1 (en) Oral care compositions
HK1198137A1 (en) Disinfecting formulations and uses thereof
EP2734194A4 (fr) Formulations de soin buccal
EP2780029A4 (fr) Formulations orales de leptine et leurs utilisations
HK1203386A1 (en) Oral care compositions
EP2533762A4 (fr) Formulations de rétinol et procédés pour leur utilisation
EP2531180A4 (fr) Composition complexe orale comprenant la pseudoéphédrine et la lévocétirizine
HK1200100A1 (en) Oral care composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140527

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150522

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/56 20060101ALI20150518BHEP

Ipc: A61K 38/05 20060101ALI20150518BHEP

Ipc: A23L 1/30 20060101ALI20150518BHEP

Ipc: C07K 14/81 20060101ALI20150518BHEP

Ipc: A61K 9/00 20060101ALI20150518BHEP

Ipc: C07K 14/575 20060101ALI20150518BHEP

Ipc: A61P 3/00 20060101ALI20150518BHEP

Ipc: A61K 38/57 20060101ALI20150518BHEP

Ipc: A61K 38/22 20060101AFI20150518BHEP

Ipc: A61K 31/575 20060101ALI20150518BHEP

Ipc: A61K 45/06 20060101ALI20150518BHEP

Ipc: A61K 31/203 20060101ALI20150518BHEP

Ipc: A61K 38/28 20060101ALI20150518BHEP

Ipc: A61K 31/198 20060101ALI20150518BHEP

Ipc: C07K 7/02 20060101ALI20150518BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151222